BibTex RIS Kaynak Göster

Sistemik isotretinoin tedavisi alan orta ve şiddetli form akne vulgarisli hastalarda hematolojik parametrelerin değerlendirilmesi

Yıl 2014, Cilt: 11 Sayı: 2, 98 - 101, 01.08.2014

Öz

Amaç: İsotretinoin ISO orta ve şiddetli form akne vulgaris tedavisinde yaygın olarak kullanılan bir oral aktif retinoik asit derivesidir. Bu çalışmada oral ISO tedavisi başlanan orta ve şiddetli form akne vulgarisli hastalarda hematolojik parametrelerin retrospektif olarak değerlendirilmesi amaçlanmıştır. Metod: Çalışmaya dermatoloji polikliniğine başvuran ve klinik olarak akne vulgaris tanısı konularak oral isotretinoin tedavisi başlanan 50 hasta alındı. Hastaların tedavi öncesi ve tedavi başlangıcından üç ay sonrasındaki hematolojik parametreleri [hemoglobin Hgb , hematokrit Htc , trobmosit Plt , ortalama platelet hacmi MPV ve lökosit WBC ] retrospektif olarak incelendi.Bulgular: Hastaların tedavi öncesi ve sonrası değerleri karşılaştırıldığında tedavi sonrası trombosit değerlerinin tedavi öncesine oranla yükseldiği, buna karşılık ortalama platelet hacminin düştüğü görüldü p0.05 . Sonuç: ISO tedavisi alan hastalarda ortalama platelet haci düşerken, platelet sayısı artmaktadır. Bu değişiklik fizyolojik sınırlar içinde omakla birlikte ISO tedavisi alan hastalar bu açıdan periyodik olarak takip edilmelidir

Kaynakça

  • 1) Well D. Acne vulgaris: A review of causes and treatment options. Nurse Pract. 2013 10;38(10):22-31.
  • 2) Bettoli V, Borghi A, Zauli S, Toni G, Ricci M, Giari S, et al. Maintenance therapy for acne vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology. 2013;227(2):97-102.
  • 3) Berk DR. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study: comment. Br J Dermatol. 2011;165(1):205.
  • 4) Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011;164(6):1369- 75.
  • 5) Kaymak Y, Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol. 2006;20(10):1256- 60.
  • 6) Boyraz N, Mustak PK. Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris. Int J Dermatol. 2013;52(10):1265-7.
  • 7) Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. An Bras Dermatol. 2012;87(3):382-7.
  • 8) Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert opinion on drug safety. 2004;3(2):119-29.
  • 9) Hensen G, Schiller M, Luger TA, Hensen P. [Psychosocial issues in outpatient care of acne vulgaris]. Gesundheitswesen. 2009;71(7):405-13.
  • 10) Akyol M, Ozcelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol. 2005;6(3):175-84.
  • 11) McIntee TJ, Bruckner AL. Challenges in optimizing isotretinoin use for acne vulgaris. JAMA dermatology. 2013;149(12):1398.
  • 12) Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576-80.
  • 13) Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J Dermatolog Treat. 2006;17(4):214-6.
  • 14) Karadag AS, Ertugrul DT, Takci Z. Isotretinoin modestly increases platelet count in acne patients. J Dermatolog Treat. 2013;24(2):139-40.
  • 15) Schmutz JL, Barbaud A, Trechot P. [Thrombocytosis induced by low-dose isotretinoin (Roaccutane(R))]. Ann Dermatol Venereol. 2002;129(3):355
  • 16) Jansen T, Altmeyer P. Thrombocytosis induced by low-dose isotretinoin. Int J Dermatol. 2000 Dec;39(12):956-7.
  • 17) Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33(5):484-6.
  • 18) Johnson TM, Rapini RP. Isotretinoin-induced thrombocytopenia. J Am Acad Dermatol. 1987;17(5 Pt 1):838-9.
  • 19) CotoSegura P, Galache C, Santos-Juanes J, Mallo-Garcia S, Curto-Iglesias JR. [Transient thrombocytopenia probably induced by isotretinoin]. Actas Dermosifiliogr. 2008;99(9):743-4.
  • 20) Hesdorffer CS, Weltman MD, Raftopoulos H, Mendelow B, Bezwoda WR. Thrombocytopenia caused by isotretinoin. S Afr Med J. 1986;70(11):705-6.
  • 21) Moeller KE, Touma SC. Prolonged thrombocytopenia associated with isotretinoin. The Annals of pharmacotherapy. 2003;37(11):1622-4.
  • 22) Aurousseau MH, Levacher S, Beneton C, Blaise M, Pourriat JL. [Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy]. Rev Med Interne. 1995;16(8):622-5.
  • 23) Ataseven A, Bilgin A. Effects of Isotretinoin on The Platelet Counts and The Mean Platelet Volume in Patients with Acne Vulgaris. The scientific world journal. 2013;21(1):11-4.

Assessment of haematological parameters in moderate to severe form acne vulgaris patients treated with systemic isotretinoin

Yıl 2014, Cilt: 11 Sayı: 2, 98 - 101, 01.08.2014

Öz

Background: Isotretinoin ISO is a new orally active retinoic acid derivative commonly used for the treatment of moderate and severe forms of acne vulgaris. In this study, treatment was started orally ISO in patients with moderate and severe forms of acne vulgaris aimed to evaluate hematological parameters retrospectively.Methods: 50 patients were enrolled who admitted to the dermatology clinic and clinically diagnosed with acne vulgaris and oral isotretinoin treatment was started. Hematological parameters before treatment and three months after onset of treatment of the patients [hemoglobin Hgb , hematocrit Hct , platelet count PLT , mean platelet volume MPV and leukocyte WBC ] were analyzed retrospectively.Results: Compared to values ​​of patients before and after treatment, after treatment platelet values has risen compared to pre-treatment, in turn, showed a decrease of mean platelet volume p 0.05 .Conclusion: ISO-treated patients mean platelet volume decreases, while the platelet count is increasing. Although these changes within the physiological limits that ISO-treated patients should be monitored periodically by these terms

Kaynakça

  • 1) Well D. Acne vulgaris: A review of causes and treatment options. Nurse Pract. 2013 10;38(10):22-31.
  • 2) Bettoli V, Borghi A, Zauli S, Toni G, Ricci M, Giari S, et al. Maintenance therapy for acne vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology. 2013;227(2):97-102.
  • 3) Berk DR. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study: comment. Br J Dermatol. 2011;165(1):205.
  • 4) Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011;164(6):1369- 75.
  • 5) Kaymak Y, Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol. 2006;20(10):1256- 60.
  • 6) Boyraz N, Mustak PK. Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris. Int J Dermatol. 2013;52(10):1265-7.
  • 7) Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. An Bras Dermatol. 2012;87(3):382-7.
  • 8) Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert opinion on drug safety. 2004;3(2):119-29.
  • 9) Hensen G, Schiller M, Luger TA, Hensen P. [Psychosocial issues in outpatient care of acne vulgaris]. Gesundheitswesen. 2009;71(7):405-13.
  • 10) Akyol M, Ozcelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol. 2005;6(3):175-84.
  • 11) McIntee TJ, Bruckner AL. Challenges in optimizing isotretinoin use for acne vulgaris. JAMA dermatology. 2013;149(12):1398.
  • 12) Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576-80.
  • 13) Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J Dermatolog Treat. 2006;17(4):214-6.
  • 14) Karadag AS, Ertugrul DT, Takci Z. Isotretinoin modestly increases platelet count in acne patients. J Dermatolog Treat. 2013;24(2):139-40.
  • 15) Schmutz JL, Barbaud A, Trechot P. [Thrombocytosis induced by low-dose isotretinoin (Roaccutane(R))]. Ann Dermatol Venereol. 2002;129(3):355
  • 16) Jansen T, Altmeyer P. Thrombocytosis induced by low-dose isotretinoin. Int J Dermatol. 2000 Dec;39(12):956-7.
  • 17) Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33(5):484-6.
  • 18) Johnson TM, Rapini RP. Isotretinoin-induced thrombocytopenia. J Am Acad Dermatol. 1987;17(5 Pt 1):838-9.
  • 19) CotoSegura P, Galache C, Santos-Juanes J, Mallo-Garcia S, Curto-Iglesias JR. [Transient thrombocytopenia probably induced by isotretinoin]. Actas Dermosifiliogr. 2008;99(9):743-4.
  • 20) Hesdorffer CS, Weltman MD, Raftopoulos H, Mendelow B, Bezwoda WR. Thrombocytopenia caused by isotretinoin. S Afr Med J. 1986;70(11):705-6.
  • 21) Moeller KE, Touma SC. Prolonged thrombocytopenia associated with isotretinoin. The Annals of pharmacotherapy. 2003;37(11):1622-4.
  • 22) Aurousseau MH, Levacher S, Beneton C, Blaise M, Pourriat JL. [Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy]. Rev Med Interne. 1995;16(8):622-5.
  • 23) Ataseven A, Bilgin A. Effects of Isotretinoin on The Platelet Counts and The Mean Platelet Volume in Patients with Acne Vulgaris. The scientific world journal. 2013;21(1):11-4.
Toplam 23 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Makalesi
Yazarlar

Yavuz Yeşilova Bu kişi benim

Enver Turan Bu kişi benim

Emin Şavik Bu kişi benim

Hatice Sezen Bu kişi benim

Yayımlanma Tarihi 1 Ağustos 2014
Yayımlandığı Sayı Yıl 2014 Cilt: 11 Sayı: 2

Kaynak Göster

Vancouver Yeşilova Y, Turan E, Şavik E, Sezen H. Sistemik isotretinoin tedavisi alan orta ve şiddetli form akne vulgarisli hastalarda hematolojik parametrelerin değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2014;11(2):98-101.

Harran Üniversitesi Tıp Fakültesi Dergisi  / Journal of Harran University Medical Faculty